Sinusoidal obstruction syndrome overview
|
Sinusoidal obstruction syndrome Microchapters |
|
Differentiating Sinusoidal obstruction syndrome from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sinusoidal obstruction syndrome overview On the Web |
|
American Roentgen Ray Society Images of Sinusoidal obstruction syndrome overview |
|
Directions to Hospitals Treating Sinusoidal obstruction syndrome |
|
Risk calculators and risk factors for Sinusoidal obstruction syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
History
The first report on veno-occlusive disease, in 1920, was as a result senecio poisoning in South Africa.[1] Subsequent reports were mostly in Jamaicans who had consumed herbal teas.[2] With the advent of bone marrow transplanation, most later reported cases have been in those undergoing treatment for leukemia.[2]
Historical Perspective
Hepatic veno-occlusive disease or sinusoidal obstruction syndrome was first described in 1905 as endophelibitis of the terminal hepatic veins. Ionizing radiations as a cause of sinusoidal obstruction syndrome was identified in the 1960's and bone marrow transplant in the 1970's. However, sinusoidal obstruction syndrome or hepatic veno-occlusive disease was a well-established concept by the mid-1960's.
Classification
Pathophysiology
In the BMT setting, VOD is felt to be due to injury to the hepatic venous endothelium from the conditioning regimen.
Toxic agents causing veno-occlusive disease include plants as well as the medication cyclophosphamide.
Causes
Differentiating Sinusoidal obstruction syndrome from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
When associated with bone marrow transplant, VOD is fatal in over 30% of cases. Cases due to plant alkaloids often have a longer and more unpredictable course.
Diagnosis
History and Symptoms
Physical Examination
Features of VOD include weight gain, tender hepatomegaly, ascites, and increased bilirubin. It often is associated with renal failure.
Laboratory Findings
Diagnosic Criteria
Imaging Findings
Ultrasound
Hepatic doppler ultrasound is typically utilized to confirm or suggest the diagnosis. Most common findings on liver doppler ultrasound include increased phasicity of portal veins with eventual development of portal flow reversal. The liver is usually enlarged but maintained normal echogenicity. A liver biopsy is required for a definitive diagnosis.
Other Diagnostic Studies
Treatment
Medical Therapy
Treatment for VOD is primarily supportive. In the BMT setting, defibrotide is an investigational treatment that may be promising. Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. Although its mechanism of action in VOD is unclear, the drug is believed to have antithrombotic properties. In August 2009, Gentium S.p.A., which sponsored the phase 3 clinical trial (pivotal) of defibrotide in hepatic VOD, announced disappointing results. Further clinical development of defibrotide for this indication is uncertain.
Surgery
Prevention
See also
- Budd-Chiari syndrome (large liver vein obstruction due to thrombosis)
References
- ↑ Willmot, F; Robertson, Georgew. (1920). "Senecio Disease, Or Cirrhosis Of The Liver Due To Senecio Poisoning". The Lancet. 196 (5069): 848. doi:10.1016/S0140-6736(01)00020-4.
- ↑ 2.0 2.1 Invalid
<ref>tag; no text was provided for refs namedHelmy